Results 21 to 30 of about 2,463,640 (351)

In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and LimitationsSummary

Cellular and Molecular Gastroenterology and Hepatology, 2023
Liver fibrosis is a common result of liver injury owing to various kinds of chronic liver diseases. A deeper understanding of the pathophysiology of liver fibrosis and identifying potential therapeutic targets of liver fibrosis is important because liver
Young-Sun Lee, Ekihiro Seki
doaj   +1 more source

Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China.

Gastroenterology, 2023
BACKGROUND & AIMS This study aimed to estimate the prevalence of liver steatosis and fibrosis in the general population and populations with potential risk factors in China, so as to inform policies for the screening and management of fatty liver disease
S. Man, Yuhan Deng, Yuan Ma, Jingzhu Fu, Heling Bao, Canqing Yu, J. Lv, Hui Liu, Bo Wang, Liming Li   +9 more
semanticscholar   +1 more source

Inhibiting IRE1α-endonuclease activity decreases tumor burden in a mouse model for hepatocellular carcinoma

eLife, 2020
Hepatocellular carcinoma (HCC) is a liver tumor that usually arises in patients with cirrhosis. Hepatic stellate cells are key players in the progression of HCC, as they create a fibrotic micro-environment and produce growth factors and cytokines that ...
Nataša Pavlović, Carlemi Calitz, Kess Thanapirom, Guiseppe Mazza, Krista Rombouts, Pär Gerwins, Femke Heindryckx   +6 more
doaj   +1 more source

Assessment and validation of the TREAT-B score to assess the treatment eligibility of patients with chronic hepatitis B virus infection

Frontiers in Medicine, 2022
Background and aimsAccess to Hepatitis B virus (HBV) DNA testing to determine treatment eligibility is limited in low-income countries. Therefore, this study aimed to assess and validate the TREAT-B score proposed as the treatment threshold in an Asian ...
Kessarin Thanapirom, Kessarin Thanapirom, Kessarin Thanapirom, Sirinporn Suksawatamnuay, Sirinporn Suksawatamnuay, Sirinporn Suksawatamnuay, Panarat Thaimai, Panarat Thaimai, Panarat Thaimai, Sombat Treeprasertsuk, Piyawat Komolmit, Piyawat Komolmit, Piyawat Komolmit, Pisit Tangkijvanich   +13 more
doaj   +1 more source

Combi-Elasto Evaluation of the Degree of Liver Fibrosis in Children with Cholestatic Liver Disease

Diagnostics, 2023
Cholestatic liver disease is a common liver disease in infants and young children. Liver fibrosis is a key factor affecting the prognosis, and liver transplantation is the only treatment option for liver cirrhosis.
Rina Li, Caihui Hu, Fenglin Xu, Qi Zhang, Fazhi Zhou, Chenpeng Zheng, Yang Gao, Yi Tang, Jingyu Chen   +8 more
doaj   +1 more source

Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression

Cells, 2021
Chronic liver injury of different etiologies may result in hepatic fibrosis, a scar formation process consisting in altered deposition of extracellular matrix.
A. Caligiuri, A. Gentilini, M. Pastore, S. Gitto, F. Marra   +4 more
semanticscholar   +1 more source

The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Biomedicines, 2022
Liver fibrosis is a key pathophysiology process in chronic liver disease. It is still unclear whether the impact of liver fibrosis is not fully realized in type 2 diabetes mellitus (T2D) patients with nonalcoholic fatty liver disease (NAFLD), and the ...
Chia-Yen Dai, Tzu-Jung Fang, Wei-Wen Hung, Hui-Ju Tsai, Yi-Chun Tsai   +4 more
doaj   +1 more source

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

Hepatology, 2021
Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non‐alcoholic fatty liver disease and alcohol‐related liver disease, although chronic ...
P. Ginés, L. Castéra, F. Lammert, I. Graupera, Miquel Serra-Burriel, A. Allen, V. Wong, Phillipp Hartmann, M. Thiele, L. Caballería, R. D. de Knegt, I. Grgurević, S. Augustin, E. Tsochatzis, J. Schattenberg, I. Guha, A. Martini, R. Morillas, M. García-Retortillo, H. D. de Koning, N. Fabrellas, J. Pich, A. Ma, Mª Alba Diaz, D. Roulot, P. Newsome, M. Manns, P. Kamath, A. Krag   +28 more
semanticscholar   +1 more source

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G, Cibu, Bianca A, Ciulei, George, Coste, Sorina C, Cozma, Angela, Mureșan, Flaviu, Negrean, Vasile, Orasan, Olga H, Ovidiu, Fabian, Pfingstgraf, Iulia O, Popovici, Ionela E, Tarmure, Simina F, Taut, Adela V. S   +12 more
core   +3 more sources

M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes. [PDF]

, 2017
Acute injury in the setting of liver fibrosis is an interesting and still unsettled issue. Most recently, several prominent studies have indicated the favourable effects of liver fibrosis against acute insults.
Bai, Li, Chen, Yu, Duan, Zhongping, Han, Yuan-Ping, Hu, Richard, Kong, Ming, Liu, Shuang, Liu, Xin, Lou, Jinli, Pandol, Stephen J, Ren, Feng, Zhang, Xiaohui, Zheng, Qingfen, Zheng, Sujun   +13 more
core   +2 more sources